Skip to Content

AptarGroup Inc ATR

Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Raising Aptar's Fair Value Estimate to $125 After Updating Our Long-Term Assumptions

Charles Gross Equity Analyst

Analyst Note

| Charles Gross |

After a periodic review of Aptar's valuation, we've raised our fair value estimate to $125 from $101 per share. The primary driver of the change is a more robust long-term growth outlook. Additionally, our near-term outlook now reflects faster growth in Aptar's pharmaceutical segment due to coronavirus vaccine tailwinds. Our narrow-moat rating remains unchanged.

Read Full Analysis

Company Profile

Business Description

AptarGroup is a leading global supplier of dispensing systems such as aerosol valves, pumps, and closures to the consumer goods and pharmaceutical markets. With the bulk of its annual net sales coming from Europe and the United States, Aptar aims to increase its presence in Asia and Latin America. Aptar's pharmaceutical division generates roughly one third of group sales but almost two thirds of group profits. We expect management to make more healthcare-related acquisitions in the coming years.

265 Exchange Drive, Suite 100
Crystal Lake, IL, 60014
T +1 815 477-0424
Sector Consumer Cyclical
Industry Packaging & Containers
Most Recent Earnings Sep 30, 2020
Fiscal Year End Dec 31, 2020
Stock Type Cyclical
Employees 14,000